Seven $1b-plus drugs seen reach­ing mar­ket in 2016

The Pak Banker - - BUSINESS -

LON­DON: Drug com­pa­nies are likely to launch seven "block­buster" drugs in 2016, each with $1 bil­lion-plus an­nual sales po­ten­tial, led by new treat­ments for liver dis­ease and HIV, ac­cord­ing to an anal­y­sis. The as­sess­ment means the phar­ma­ceu­ti­cals in­dus­try is on track for an­other pro­duc­tive year, al­though not as good as 2015, which saw the ar­rival of 11 new block­busters. The two top hits of 2016 are tipped to be In­ter­cept Phar­ma­ceu­ti­cals' (ICPT.O) chronic liver dis­ease drug obeti­cholic acid, with a con­sen­sus sales fore­cast of $2.6 bil­lion in 2020, and Gilead Sci­ences' (GILD.O) new fixed dose HIV drug emtric­itabine plus teno­fovir alafe­namide, on $2.0 bil­lion. Other prod­ucts ex­pected to launch this year with fore­cast sales above $1 bil­lion in 2020 in­clude a new hep­ati­tis C drug from Merck (MRK.N) and a leukemia medicine from Ab­b­Vie (ABBV.N), ac­cord­ing to the an­nual "Drugs to Watch" re­port. Two keenly awaited Roche (ROG.VX) drugs, each with fore­cast sales of around $3 bil­lion, are not on list be­cause it is un­clear if ate­zolizumab for can­cer and ocre­lizumab for mul­ti­ple scle­ro­sis will be com­mer­cially avail­able this year or next.

Newspapers in English

Newspapers from Pakistan

© PressReader. All rights reserved.